FDA Grants Accelerated Approval to Neladalkib for ALK+ NSCLC After Alectinib or Multiple Therapies plus Chemo

Adults with ALK-positive lung cancer that has stopped responding to alectinib have a new option: on Tuesday the U.S. Food and Drug Administration granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.), a once-daily pill that shrank tumors in roughly half of patients who had received only one prior ALK inhibitor.

The approval covers adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) whose disease progressed after either one prior ALK tyrosine kinase inhibitor consisting of alectinib, or two or more prior ALK inhibitors plus platinum-based chemotherapy. The decision, which the U.S. Food and Drug Administration reported on November 17, 2026, arrives under the agency’s accelerated approval pathway.

For patients, the practical change is straightforward: a 150 mg tablet taken by mouth once a day, with or without food, at the same time each day, until the cancer progresses or unacceptable toxicity.

What makes this matter is where neladalkib sits in the treatment sequence. Neladalkib, a kinase inhibitor, is designed to block that signaling — including, according to data reported in source material, tumors carrying the ALK G1202R mutation, which appeared in 19% of trial participants.

FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
Photo: onclive.com

Nelkarmi shrinks tumors in ALK-positive lung cancer

  • Nelkarmi is a daily pill approved for ALK-positive lung cancer that has grown after alectinib or after multiple ALK drugs and chemotherapy.
  • Tumors shrank in 49% of patients who had only alectinib before, and in 32% of heavily pretreated patients — and most responses lasted at least six months.
  • The main side effects involve the liver, kidneys, eyes, muscles and nerves, so regular monitoring will be part of treatment.

What the ALKOVE-1 trial showed

ALKOVE-1 (NCT05384626) supplied the supporting data — a multicenter, single-arm, open-label, multi-cohort study that enrolled 67 patients whose only prior metastatic ALK TKI was alectinib and 155 patients who had already been treated with two or more prior ALK TKIs along with platinum-based chemotherapy.

The U.S. Food and Drug Administration’s efficacy evaluation rested on 67 patients who had received alectinib as their only prior ALK inhibitor and 155 who had received two or more prior ALK inhibitors plus platinum chemotherapy.

In the alectinib-pretreated group, the confirmed overall response rate — the share of patients whose tumors shrank measurably — was 49% (95% CI: 37, 62). Among those who responded, 76% held their response for at least six months and 52% for at least a year. In the more heavily pretreated group, the response rate was 32% (95% CI: 24, 40), with 69% of responses lasting at least six months and 51% at least twelve months.

Patient group Patients Tumor shrinkage (ORR) Response ≥ 6 months Response ≥ 12 months
One prior ALK TKI (alectinib) 67 49% 76% 52%
Two or more prior ALK TKIs + platinum chemotherapy 155 32% 69% 51%

Findings unveiled at the 2026 ASCO Annual Meeting demonstrated a 46% ORR (95% CI, 33%-59%) among patients who had never received lorlatinib (n = 63) versus 26% (95% CI, 20%-33%) among those previously treated with lorlatinib (n = 190); median progression-free survival came to 14.5 months (95% CI, 4.8-not estimable) in the lorlatinib-naive group and 4.6 months (95% CI, 2.8-6.2) in those with prior lorlatinib exposure.

How the safety picture compares

The prescribing information carries warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity, meaning the drug can harm a developing fetus. The most common adverse reactions (≥20%) were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue.

According to the source material, the lab findings point to specific red flags for patients: any change in vision, muscle pain or weakness without an obvious cause, or indicators of liver problems — including yellowing of the skin or dark-colored urine — should be reported, and patients are advised to discuss contraception with their physician while on the drug.

Most transaminase rises observed in the trial appear to have been symptom-free lab findings that stayed mild, resolved on their own, and could be managed through holding or lowering the dose — treatment-emergent adverse effects (TEAEs) prompted dose reductions in 17% of patients (n = 656), driven most often by elevated alanine aminotransferase (ALT; 10%) and aspartate aminotransferase (AST; 8%) levels.

FDA Approves Nelkarmi for Previously Treated ALK+ Lung Cancer
Photo: curetoday.com

Who paid for the trial, and what regulators did

Nuvalent, Inc., the drug’s developer, sponsored the application; the regulatory filing used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The application was granted priority review, and neladalkib received breakthrough therapy designation and orphan drug designation.

In the ongoing phase 3 ALKAZAR trial (NCT06765109), neladalkib is going head to head with alectinib in patients with advanced ALK-positive NSCLC who have not yet received a TKI, and the protocol builds in intensified surveillance along with rapid dose adjustments when transaminase levels climb.

Access beyond the United States remains an open question. The FDA decision governs U.S. patients; European and British patients would need separate reviews by the European Medicines Agency or the UK’s licensing bodies before neladalkib becomes available through those systems. No such filings are addressed in the current reports.

Contraindications & When to Consult a Doctor

The prescribing information does not list absolute contraindications, but it flags embryo-fetal risk, so pregnancy and breastfeeding require an explicit discussion with the treating oncologist before starting. Patients should contact their care team promptly for yellowing skin or eyes, dark urine, vision changes, unexplained muscle pain or weakness, or new numbness and tingling.

Any serious adverse event that clinicians suspect may be linked to a medicine or device should be submitted to FDA’s MedWatch Reporting System, or reported by calling 1-800-FDA-1088; the complete prescribing information will be available on Drugs@FDA.

The question ALKAZAR must answer

Accelerated approval is a provisional verdict, not a final one. Whether neladalkib actually extends survival — and whether it beats alectinib as a first treatment rather than a salvage option — will only be settled when the phase 3 ALKAZAR trial reads out, a milestone the current reports do not date.

References

  • U.S. Food and Drug Administration. “FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer.” November 17, 2026.
  • OncLive. “FDA approves neladalkib for locally advanced or metastatic ALK-positive NSCLC.”
  • CURE. “FDA approves neladalkib for previously treated ALK-positive lung cancer.”
  • ALKOVE-1 trial registration, ClinicalTrials.gov identifier NCT05384626.

Photo of author

Health Desk

Health Desk at Archyde.

Colorado Upsets Houston, Utah Beats Arizona in Big 12